ORIC Pharmaceuticals Q4 2025 Financial Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy ORIC?
Source: seekingalpha
- Earnings Beat: ORIC Pharmaceuticals reported a Q4 2025 GAAP EPS of -$0.30, exceeding market expectations by $0.06, indicating potential improvement in financial performance.
- Cash Reserves Increase: As of December 31, 2025, the company reported cash, cash equivalents, and investments totaling $392.3 million, including $124.4 million from a private placement in May 2025, reflecting enhanced fundraising capabilities.
- Successful Follow-On Financing: Subsequent to Q4 2025, ORIC raised an additional $20 million in net proceeds through its ATM program, bringing total cash and investments to $412.3 million as of December 31, 2025, ensuring robust funding for future operations.
- Operational Plan Assurance: The company expects its current cash and investments to fund its operational plan into the second half of 2028, demonstrating a solid strategic positioning for R&D and market expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORIC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORIC
Wall Street analysts forecast ORIC stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 13.510
Low
15.00
Averages
19.60
High
25.00
Current: 13.510
Low
15.00
Averages
19.60
High
25.00
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ORIC Pharmaceuticals Reports Narrower Q4 Loss
- Improved Loss Metrics: ORIC Pharmaceuticals reported a narrower net loss of $30.51 million for Q4, translating to a loss of $0.30 per share, down from $36.31 million and $0.51 per share in the previous year, indicating positive financial management efforts.
- Reduced R&D Expenses: The company saw a decrease in R&D expenses to $25.86 million in Q4 from $31.97 million year-over-year, reflecting effective cost control measures that contribute to the overall reduction in operational losses.
- Widened Annual Loss: Despite the improved quarterly performance, ORIC's full-year net loss widened to $129.47 million from $127.85 million, highlighting ongoing challenges faced during the clinical development phase.
- Strong Cash Position: As of December 31, 2025, ORIC's cash, cash equivalents, and investments totaled $392.3 million, ensuring the company can continue to support its R&D projects, particularly for its clinical candidates targeting prostate cancer and non-small cell lung cancer.
See More
ORIC Pharmaceuticals Q4 2025 Financial Highlights
- Earnings Beat: ORIC Pharmaceuticals reported a Q4 2025 GAAP EPS of -$0.30, exceeding market expectations by $0.06, indicating potential improvement in financial performance.
- Cash Reserves Increase: As of December 31, 2025, the company reported cash, cash equivalents, and investments totaling $392.3 million, including $124.4 million from a private placement in May 2025, reflecting enhanced fundraising capabilities.
- Successful Follow-On Financing: Subsequent to Q4 2025, ORIC raised an additional $20 million in net proceeds through its ATM program, bringing total cash and investments to $412.3 million as of December 31, 2025, ensuring robust funding for future operations.
- Operational Plan Assurance: The company expects its current cash and investments to fund its operational plan into the second half of 2028, demonstrating a solid strategic positioning for R&D and market expansion.
See More
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent demand for registration-ready assets, positioning Oncolytics Biotech at the forefront of this growth wave.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to drive the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: In third-line data for anal cancer, pelareorep achieved a 29% objective response rate, nearly tripling historical benchmarks, with a median duration of response reaching approximately 17 months, showcasing its potential in a setting with no FDA-approved treatment options.
- FDA Study Design Approval: Oncolytics has secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
Oncolytics Biotech Accelerates Cancer Treatment Progress, Aiming for FDA Approval in 2026
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent need for registration-ready assets, positioning Oncolytics Biotech as a key investment opportunity.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will drive the company's registration programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks in a setting with no FDA-approved treatment options, indicating significant clinical potential and likely accelerating the approval process for anal cancer.
- FDA Study Design Endorsement: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the company's unique position in the immunotherapy registration trial landscape and expected to drive future market opportunities.
See More
ORIC Pharmaceuticals to Present Drug Developments at 44th J.P. Morgan Healthcare Conference
- Conference Presentation: ORIC Pharmaceuticals CEO Jacob M. Chacko will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, showcasing the latest advancements in their oncology drug development, which is expected to attract investor interest.
- Live Webcast: The presentation will be available via live webcast on the investor section of the company’s website, with a replay accessible for 90 days post-event, ensuring that investors unable to attend live can still access critical information.
- Product Candidates: ORIC's clinical-stage candidates include ORIC-944, an allosteric inhibitor for prostate cancer, and enozertinib (ORIC-114), targeting various genetically defined cancers, highlighting the company's potential in innovative drug development aimed at overcoming therapeutic resistance.
- Company Background: ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving patient lives by overcoming resistance in cancer, with offices in South San Francisco and San Diego, indicating a strategic presence in California's biotech hub.
See More
ORIC Pharmaceuticals (ORIC) Rises Following Promising ESMO Asia Data for Enozertinib, Leading Wells Fargo to Increase Valuation
Price Target Increase: Wells Fargo raised the price target for ORIC Pharmaceuticals from $19 to $25, maintaining an Overweight rating, indicating confidence in the company's potential for growth.
Financial Position: As of September 30, ORIC Pharmaceuticals reported approximately $413 million in cash and investments, which is expected to support its operations through 2028 and fund upcoming Phase 3 trials.
Clinical Development: The company is making significant progress towards initiating Phase 3 trials for its lead candidates, ORIC-944 and enozertinib, which are anticipated to yield important data in the near future.
Investment Considerations: While ORIC is seen as a promising investment, there are suggestions that certain AI stocks may offer better upside potential with lower risk, highlighting a competitive investment landscape.
See More
ORIC Pharmaceuticals Reports Narrower Q4 Loss
- Improved Loss Metrics: ORIC Pharmaceuticals reported a narrower net loss of $30.51 million for Q4, translating to a loss of $0.30 per share, down from $36.31 million and $0.51 per share in the previous year, indicating positive financial management efforts.
- Reduced R&D Expenses: The company saw a decrease in R&D expenses to $25.86 million in Q4 from $31.97 million year-over-year, reflecting effective cost control measures that contribute to the overall reduction in operational losses.
- Widened Annual Loss: Despite the improved quarterly performance, ORIC's full-year net loss widened to $129.47 million from $127.85 million, highlighting ongoing challenges faced during the clinical development phase.
- Strong Cash Position: As of December 31, 2025, ORIC's cash, cash equivalents, and investments totaled $392.3 million, ensuring the company can continue to support its R&D projects, particularly for its clinical candidates targeting prostate cancer and non-small cell lung cancer.
See More
ORIC Pharmaceuticals Q4 2025 Financial Highlights
- Earnings Beat: ORIC Pharmaceuticals reported a Q4 2025 GAAP EPS of -$0.30, exceeding market expectations by $0.06, indicating potential improvement in financial performance.
- Cash Reserves Increase: As of December 31, 2025, the company reported cash, cash equivalents, and investments totaling $392.3 million, including $124.4 million from a private placement in May 2025, reflecting enhanced fundraising capabilities.
- Successful Follow-On Financing: Subsequent to Q4 2025, ORIC raised an additional $20 million in net proceeds through its ATM program, bringing total cash and investments to $412.3 million as of December 31, 2025, ensuring robust funding for future operations.
- Operational Plan Assurance: The company expects its current cash and investments to fund its operational plan into the second half of 2028, demonstrating a solid strategic positioning for R&D and market expansion.
See More
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent demand for registration-ready assets, positioning Oncolytics Biotech at the forefront of this growth wave.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to drive the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: In third-line data for anal cancer, pelareorep achieved a 29% objective response rate, nearly tripling historical benchmarks, with a median duration of response reaching approximately 17 months, showcasing its potential in a setting with no FDA-approved treatment options.
- FDA Study Design Approval: Oncolytics has secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
See More
Oncolytics Biotech Accelerates Cancer Treatment Progress, Aiming for FDA Approval in 2026
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent need for registration-ready assets, positioning Oncolytics Biotech as a key investment opportunity.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will drive the company's registration programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks in a setting with no FDA-approved treatment options, indicating significant clinical potential and likely accelerating the approval process for anal cancer.
- FDA Study Design Endorsement: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the company's unique position in the immunotherapy registration trial landscape and expected to drive future market opportunities.
See More
ORIC Pharmaceuticals to Present Drug Developments at 44th J.P. Morgan Healthcare Conference
- Conference Presentation: ORIC Pharmaceuticals CEO Jacob M. Chacko will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, showcasing the latest advancements in their oncology drug development, which is expected to attract investor interest.
- Live Webcast: The presentation will be available via live webcast on the investor section of the company’s website, with a replay accessible for 90 days post-event, ensuring that investors unable to attend live can still access critical information.
- Product Candidates: ORIC's clinical-stage candidates include ORIC-944, an allosteric inhibitor for prostate cancer, and enozertinib (ORIC-114), targeting various genetically defined cancers, highlighting the company's potential in innovative drug development aimed at overcoming therapeutic resistance.
- Company Background: ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving patient lives by overcoming resistance in cancer, with offices in South San Francisco and San Diego, indicating a strategic presence in California's biotech hub.
See More
ORIC Pharmaceuticals (ORIC) Rises Following Promising ESMO Asia Data for Enozertinib, Leading Wells Fargo to Increase Valuation
Price Target Increase: Wells Fargo raised the price target for ORIC Pharmaceuticals from $19 to $25, maintaining an Overweight rating, indicating confidence in the company's potential for growth.
Financial Position: As of September 30, ORIC Pharmaceuticals reported approximately $413 million in cash and investments, which is expected to support its operations through 2028 and fund upcoming Phase 3 trials.
Clinical Development: The company is making significant progress towards initiating Phase 3 trials for its lead candidates, ORIC-944 and enozertinib, which are anticipated to yield important data in the near future.
Investment Considerations: While ORIC is seen as a promising investment, there are suggestions that certain AI stocks may offer better upside potential with lower risk, highlighting a competitive investment landscape.
See More
